These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14747959)

  • 1. Risk of second primary cancer following differentiated thyroid cancer.
    Berthe E; Henry-Amar M; Michels JJ; Rame JP; Berthet P; Babin E; Icard P; Samama G; Galateau-Sallé F; Mahoudeau J; Bardet S
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):685-91. PubMed ID: 14747959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
    Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
    Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
    Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
    Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Italian cancer figures, report 2013: Multiple tumours.
    AIRTUM Working Group
    Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
    Gandhi S; Abhyankar A; Basu S
    Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
    Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
    Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
    Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
    J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence?
    Cappagli V; Caldarella A; Manneschi G; Piaggi P; Bottici V; Agate L; Molinaro E; Bianchi F; Elisei R
    Int J Cancer; 2020 Nov; 147(10):2838-2846. PubMed ID: 32449158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.
    Lang BH; Lo CY; Wong IO; Cowling BJ
    Surgery; 2010 Dec; 148(6):1191-6; discussion 1196-7. PubMed ID: 21134551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
    Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
    Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
    Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.
    Dottorini ME; Lomuscio G; Mazzucchelli L; Vignati A; Colombo L
    J Nucl Med; 1995 Jan; 36(1):21-7. PubMed ID: 7799075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
    Brierley J; Tsang R; Panzarella T; Bana N
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):418-27. PubMed ID: 16181234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiated thyroid carcinoma referred for radioiodine therapy.
    Al-Balawi IA; Meir HM; Yousef MK; Nayel HA; Al-Mobarak MF
    Saudi Med J; 2001 Jun; 22(6):497-503. PubMed ID: 11426239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
    Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
    J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second malignant neoplasms following childhood cancer: a study of a recent cohort (1987-2004) from the childhood cancer registry of the Rhône-Alpes region (ARCERRA) in France.
    Berger C; Trombert-Paviot B; Casagranda L; Mialou V; Frappaz D; Plantaz D; Collardeau-Frachon S; Freycon F
    Pediatr Hematol Oncol; 2011 Aug; 28(5):364-79. PubMed ID: 21736475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.